Modern Slavery Act Statement

Thermo Fisher Scientific Inc.’s (“Thermo Fisher”, “we” or the “Company”) 4i Values of Integrity, Intensity, Innovation and Involvement are the foundation of our culture, guiding all interactions with our customers, suppliers, partners, communities, and each other. As the first of these values, Integrity reminds our colleagues to honor commitments, communicate openly and demonstrate the highest ethical standards. This includes a commitment to ensuring that our own operations and our supply chain respect human rights and fair labor practices, and uphold global standards for equal opportunities, the freedom to associate, as well as the elimination of modern slavery, human trafficking, and harmful or exploitative forms of child labor.

This statement is made pursuant to:

  • the California Transparency in Supply Chains Act (“California Act”),
  • section 54(1) of the UK Modern Slavery Act (“UK Act”),
  • the reporting requirements under the Commonwealth of Australia Modern Slavery Act (“Australian Act”),
  • the Norwegian Transparency Act (“Norwegian Act”),
  • the Swiss Ordinance on Due Diligence and Transparency in relation to Minerals and Metals from Conflict-Affected Areas and Child Labor (“VSoTr”)1, and
  • the Canadian Fighting Against Forced Labor and Child Labor in Supply Chains Act (“Canadian Act” and, collectively, the “Acts”).

This statement constitutes our human rights and modern slavery transparency statement for the financial year ending 31 December 2024 and was approved by the Thermo Fisher Board of Directors on 20 May 2025. Our previous human rights and modern slavery statements are available in the “Corporate Social Responsibility”  section of our website under the heading “Global Supply Chain,” which can be found here.

Organization Structure

Thermo Fisher, as parent company of the Thermo Fisher group of companies (the “Group”), issues this statement on behalf of itself and each of its subsidiaries that are subject to each of the Acts, respectively, and in particular, its subsidiaries listed in Annexes I to V, which have conferred and collaborated in the preparation, review and finalization of this statement.

Thermo Fisher is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences medicines, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

We report our business in four segments - Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

Our supply chain includes tens of thousands of suppliers globally. These suppliers provide the raw materials we use for manufacturing, services to support our research teams and the lab equipment, chemicals, and other vital goods used across our manufacturing and service network around the world. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials and components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.

For more information regarding our business, please see the “Business” section of our Annual Report on Form 10-K for the year ended 31 December 2024, which can be found here.

More information about our supply chain is available in the “Corporate Social Responsibility” section of our website under the heading “Global Supply Chain,” which can be found here.

Our Policies and Guidelines

As a signatory to the UN Global Compact (“UNGC”), Thermo Fisher is committed to aligning corporate strategy with the Ten Principles on human rights, labor, environment and anti- corruption and to the applicable laws and fair labor practices, as evidenced by the following Company policies:

These policies help us implement a human rights framework aligned with leading international standards, including the UN Universal Declaration of Human Rights and the International Labour Organization (“ILO”) Declaration on Fundamental Principles and Rights at Work. Our approach references the United Nations Guiding Principles on Business and Human Rights (“UNGP”) and the Organisation for Economic Co-operation and Development (“OECD”) Guidelines for Multinational Enterprises (“OECD Guidelines”). When differences arise between our standards and legal requirements, we apply the stricter standard.

With the rapid evolution of technology, society’s needs, and stakeholder expectations, we continue to strengthen our policies and business processes for identifying, assessing and managing human rights risks, including by conducting periodic internal reviews of our systems

Human Rights and Equal Opportunity Policy

The Thermo Fisher Human Rights and Equal Opportunity Policy (the “Human Rights Policy”) outlines principles and commitments for the Company’s operations, which include the prohibition of forced labor, prison labor and trafficking in persons; prohibition of child labor; non-discrimination and equal opportunity; fair treatment; adequate wages, benefits and working hours; freedom of association; as well as healthy and safe work standards. It applies to all Thermo Fisher employees, contractors, agents, and other partners through whom Thermo Fisher conducts business.

Our Code of Business Conduct and Ethics

The Thermo Fisher Code of Business Conduct and Ethics (the “Code of Conduct”) is translated into 21 languages and covers a broad range of topics, including policies related to conflicts of interest, honest and ethical fair dealing, bribery and improper payments, insider trading, export control awareness, human rights, privacy matters, respectful interactions at work and harassment. It applies to all Thermo Fisher employees and sets forth our commitment to conduct business with the highest ethical standards and to comply with all applicable laws and regulations. Violations are not tolerated and may lead to disciplinary action, up to and including termination.

Supplier Code of Conduct

The Thermo Fisher Supplier Code of Conduct (“Supplier Code”) outlines expectations for our suppliers/partners and their subcontractors in the areas of ethics, human rights, health and safety, environmental responsibility, and management systems. In 2024, we reviewed our Supplier Code to maintain expectations associated with local laws and regulations. These expectations are in line with our corporate values, the Code of Conduct and the UNGC’s Ten Principles, and include:

  • prohibitions on use of child labor, as described in Minimum Age Convention 138 and Worst Forms of Child Labor Convention 182 of the International Labor Organization,

  • prohibitions on forced labor/prison labor, as described in Article 2 in the Forced Labor Convention 29 and Article 1 in the Abolition of Forced Labor Convention 105 of the International Labor Organization,

  • requirement to comply with all applicable labor laws, rules, and regulations, including but not limited to, all laws forbidding the solicitation, facilitation, or any other use of slavery, servitude, forced or compulsory labor or human trafficking,

  • requirements for our suppliers to provide all information or material required to enable Thermo Fisher to ensure compliance with such laws, rules, and regulations, and commitments to responsible sourcing practices, including: (i) taking appropriate health and safety measures, (ii) acting in an environmentally responsible manner, (iii) commitments to non-discrimination and equal opportunity, and fair treatment.

The Supplier Code is also integrated into supply agreements and terms and conditions, and suppliers are expected to share their performance against Supplier Code expectations at our request. Thermo Fisher reserves the right to take appropriate contractual measures up to and including contract termination where necessary and appropriate as outlined in the Supplier Code.

Complaint Procedures – Global Ethics Hotline

We encourage reporting and offer a number of resources for the reporting of illegal or unethical behavior in our operations or in our supply chain, such as our confidential Global Ethics Hotline (“Ethics Hotline”). The Ethics Hotline is our telephone and web-based hotline maintained by a third party for the purpose of gathering information regarding compliance and ethics concerns. It is available to colleagues, customers and other external stakeholders such as suppliers and workers in the supply chain, to raise concerns, anonymously if requested, related to any issue, observed or suspected, including human rights issues, and violation of any law, regulation, or any Company policies.

In addition, and in line with our company’s value of Integrity, anyone can report human rights-, ethics-, and compliance-related concerns directly to any level of internal leadership, as well as to Legal or Human Resources representatives.

Reports of violations of law, or any Company policies are rigorously investigated and documented.

Our non-retaliation policy ensures that retaliation against any person who lawfully and in good faith seeks advice, raises a concern, reports misconduct, or provides information in an investigation is strictly prohibited and will not be tolerated.

The Supplier Code also prohibits any supplier’s unlawful retaliation against its employees, including the threat of reprisal, intimidation, or harassment, for reporting violations or cooperating in investigations.

Due Diligence, Risk Assessment and Management

We have developed processes and management systems to appropriately identify and assess adverse impacts, prevent or mitigate these impacts or provide for remediation when appropriate, and track implementation, as informed by the OECD Due Diligence Guidance for Responsible Business Conduct (“OECD Guidance”). In 2024, we continued oversight of our human rights management approach, via our designated Global Human Rights Counsel. The role has responsibility for leading the coordination of our legal human rights program across all businesses. This appointment strengthens awareness, compliance and adherence to governing principles and ethical and legal codes. The Global Human Rights Counsel reports to senior management on a regular basis.

During the year, we continued to enhance our human rights due diligence practices. This included in-depth human rights risk assessment of our operations and supplier network in compliance with regulatory requirements. Our assessments indicate that human rights risks, including forced and child labor risks, in our operations in the aggregate remain low. This is primarily due to our company-wide applicable standards, and the preventive and mitigating measures that we have implemented in our standard processes, such as comprehensive policies, employee training, personnel documentation checks, use of working time management systems, and environmental, health and safety (“EHS”) site audits and certifications. A new internal oversight process enables the company to more regularly monitor human rights-related matters, and continue to identify, assess and manage human rights risks.

We source components globally that are used both at our facilities and by our external partners to manufacture our products. With such a global structure, the supply chain is the main area where Thermo Fisher is at the highest risk for adverse human rights impacts.

Thermo Fisher expects suppliers to treat their employees with dignity and respect, to comply with all legal and regulatory requirements pertaining to the fair treatment of employees, and to proactively assess and monitor their subcontractors to ensure they abide by the same principles. We are committed to implementing effective systems and controls to ensure that our suppliers recognize our position in relation to compliance with all applicable laws and regulations.

Our risk-based approach to supplier engagement and monitoring allows us to focus our resources on areas that we believe have the largest potential impact. Our supply chain risk assessment starts with evaluating all suppliers based on geography and industry by risk ranking locations and industries where risks of labor, human rights, or environmental issues are generally highest. This risk assessment references external sustainability sources and indices including from WRI, WHO, UNDP, ILO, The World Bank and the Corruption Perception Index, as well as a large database of actual corporate performance on labor, human rights, and environmental topics. Globally, the percentage of our supply chain that falls into the highest risk portion of this assessment represents less than 1% of all suppliers.

Following this comprehensive process, we further seek to prioritize areas for direct supplier assessment. In 2024, we executed detailed supplier engagement initiatives focusing on suppliers who:

  • demonstrated highest risk in the industry and geography specific assessment described above,
  • provided products that are likely to contain minerals at risk of being sourced from conflict affected areas,
  • performed insufficiently in earlier assessments or demonstrated some other type of residual risk, or were otherwise considered strategic for our businesses.

Human rights are integrated into our follow-on supplier due diligence process, where indicators such as the risk of child labor, the risk of modern slavery, the right of freedom of association, and the decency of working conditions are evaluated.

In 2024, Thermo Fisher utilized multiple mechanisms to conduct due diligence to evaluate and address modern slavery risks, such as third-party reviewed supplier assessments, including specific human rights assessments, and onsite auditing. These mechanisms allow us to monitor compliance with our Supplier Code and to assess and accelerate improvements in supplier practices.

Third-party assessments were conducted for the following targeted supplier populations:

  • suppliers representing the top 71% of spend for the Fisher Scientific distribution channel,
  • suppliers representing the top 63% of direct materials spend for our self-manufactured product portfolio, and
  • suppliers who were identified as high-risk based on the risk assessment criteria described above.

Additionally, where suppliers who fall outside the targeted supplier populations voluntarily share the results of a supplier assessment completed for another customer, Thermo Fisher included such assessments in our program. For all assessments received in the previous 2 years (2023 and 2024), greater than 79% represented at least “good” management practice, and less than 1% were identified as having “insufficient” performance.

In all cases, where performance is deemed “insufficient” or “partial”, corrective action plans are requested from suppliers to drive continuous improvement. Thermo Fisher monitors these suppliers to confirm that the corrective action plans are implemented, and suppliers are reassessed in twelve months’ time. Suppliers who persistently refuse to participate or do not demonstrate continuous improvement are targeted for escalated engagement, potentially including a third-party, onsite audit.

Additionally, more specific supplier engagement was undertaken for additional investigation in the following areas:

  • Due diligence activities associated with responsible sourcing of materials containing or consisting of tin, tantalum, tungsten and gold. Detailed information is available in our conflict minerals report which can be found here.
  • Activities to investigate and respond to relevant governmental orders or restrictions, such as Withhold Release Orders (WROs) by the Commissioner for U.S. Customs and Border Protection on concerns of use of forced labor in the U.S. supply chain.

Finally, for certain suppliers representing particularly high business risk, onsite audits, all of which were announced, were conducted by third-party independent auditors covering compliance, ethical trading, labor regulations and standards, and responsible production practices. Where onsite audits identified findings, corrective action plans were developed and mutually agreed upon between the Company and the supplier and follow-up activities were conducted to confirm issues were resolved. In all audits completed in 2024, no major findings were identified.

Training

All employees globally receive compulsory annual training on the ethical and human rights principles and standards outlined in our Code of Conduct and the Human Rights and Equal Opportunity Policy. This training is offered in 21 languages and mapped to the regions where employees are based.

As Thermo Fisher continually improves responsible procurement processes and champions suppliers’ sustainability initiatives, in 2024 we have advanced our education offerings, as follows:

  • providing a series of live webinars on supplier responsibility topics, such as sustainability performance ratings and the Supplier Code,
  • maintaining our introduction to supplier responsibility training course, which has been taken by over 800 Thermo Fisher procurement colleagues since inception and is now included in standard onboarding training for new procurement colleagues,
  • holding our inaugural Asia Pacific regional virtual supplier day event focusing on sustainability topics in the supply chain, and
  • computer-based training courses, covering topics such as introduction to sustainability, sustainability management systems, and policy development in the areas of environment, human rights and labor, ethics and sustainable procurement, in which more than 700 suppliers participated.

Thermo Fisher also continued its work with the Sustainable Procurement Pledge, an international, non-profit organization for procurement professionals, academics, and practitioners, driving awareness and knowledge of responsible sourcing practices. 

Monitoring our Effectiveness in Mitigating Negative Human Rights Impacts by our Business Activities and Relationships, and Combatting Slavery, Child Labor and Human Trafficking

Thermo Fisher will continue to review and improve its practices to respect human rights for rightsholders affected by our business and identify and eliminate, to the fullest extent practicable, modern slavery, child labor or human trafficking from our business and supply chain. To maintain and continually improve our own operational and supply chain performance we:

  • work on improving risk assessment tools,
  • share best practices and work with our key suppliers to reduce supply chain risks,
  • regularly review our human rights policies as outlined above to drive alignment with global regulatory and business best practices,
  • monitor and work to improve supplier diligence response rates via targeted initiatives,
  • target supplemental training for suppliers in high-risk regions/sectors,
  • monitor the effectiveness of our Code of Conduct training, taking into account scope and audience, questions and answers content, employee attestation of completion and compliance with required standards and completion rates,
  • track EHS progress from the company level to the site level using key metrics
  • track, investigate and drive the remediation of any complaints received and substantiated related to human rights in our operations or supply chain, and
  • conduct annual effectiveness review of our Ethics Hotline.

An overview of select performance indicators organized around the pillars of our Corporate Social Responsibility strategy, including human rights topics, is available in the “Corporate Social Responsibility” section of our website, which can be found here. Our reporting includes a data summary section that provides a consolidated and historical view of these performance indicators, measuring the effectiveness of our efforts. Based on our efforts, including due diligence, we have no indication that our operations or those of our suppliers are negatively impacting human rights.

Our actions as described above support the Thermo Fisher long-term commitment to respect the human rights of all people and to improve the quality of life in the communities we serve.

Signed on behalf of Thermo Fisher Scientific Inc.

Signature

Marc N. Casper

Chairman, President, and Chief Executive Officer

Annex

Annex I

Commonwealth of Australia Modern Slavery Act

1. Reporting Subsidiaries

All of the entities listed below are fully owned indirect subsidiaries of Thermo Fisher Scientific Inc. registered in Australia, and are considered Reporting Subsidiaries under the Australian Act:

FEI Melbourne Pty Ltd

FEI Australia Pty Ltd

Fisher Scientific Australia Pty Ltd

Oxoid Australia Pty Ltd

Thermo Gamma-Metrics Holdings Pty Ltd

Thermo Gamma-Metrics Pty Ltd

Thermo Electron Australia Pty Ltd

Thermo Trace Pty Ltd

Thermo Fisher Scientific Australia Pty Ltd

Lomb Scientific (Aust) Pty Ltd

Technology Design Solutions Pty Ltd

App-tek International Pty Ltd

Patheon Biologics Australia Pty Ltd

PPD Australia Pty Limited

Thermo Fisher operates entities across all business groups in Australia. The Company maintains manufacturing sites located in Brisbane, Melbourne, and Thebarton. With approximately 1,300 employees as of December 31, 2024, Thermo Fisher's Australian operations encompass a wide range of functions, including sales and marketing, distribution, purchasing and procurement, manufacturing, research and development, and support services. The Company engages in clinical research and the contract manufacturing of protein therapeutic drug substances utilizing single-use technology.

2. Addressing modern slavery risks in Australian operations and its supply chain

All Reporting Subsidiaries adhere to the Company’s policies and procedures and are subject to the risk management strategy detailed in this Transparency Statement, including due diligence, risk assessment of operations and supply chain, and all preventive and mitigating measures discussed herein.

 

Annex II

The Canadian Fighting Against Forced Labor and Child Labor in Supply Chains Act

1. Reporting Subsidiaries

All of the entities listed below are fully owned indirect subsidiaries of Thermo Fisher Scientific Inc. registered and/or doing business in Canada, and are considered Reporting Subsidiaries under the Canadian Act:

Fisher Scientific Company / Société Fisher Scientifique

Life Technologies Inc. Technologies Life Inc.

PPD Canada, Ltd.

Thermo CRS Ltd.

Thermo Fisher Scientific (Mississauga) Inc.

Patheon Inc.

Fisher Clinical Services Inc.

Thermo Electron North America LLC

Thermo Fisher’s Reporting Subsidiaries in Canada primarily engage in selling and distributing a wide range of laboratory and scientific equipment, laboratory chemicals and reagents, integrated laboratory workflow solutions, and consumables. Our Canadian operations also include the provision of comprehensive, integrated drug development, laboratory and lifecycle management services to the biopharmaceutical, biotechnology, and medical device industries, as well as the design, manufacturing, distribution, and servicing of automated operational processes in life sciences.

The manufacturing entity, Patheon Inc., covers all phases of drug product development from early-phase formulation to clinical trial material to commercial supply.

In total, our Canadian Reporting Subsidiaries employed approximately 2,800 employees as of December 31, 2024.

In addition, two US entities are considered Reporting Subsidiaries under the Canadian Act: Thermo Electron North America LLC, which provides a variety of scientific and laboratory instruments, equipment, and related services, and Fisher Clinical Services Inc., offering clinical trial support services.

2. Addressing forced and child labor risks in Canadian operations and its supply chain

All Reporting Subsidiaries adhere to the Company’s policies and procedures and are subject to the risk management strategy detailed in this Transparency Statement, including due diligence, risk assessment of operations and supply chain, and all preventive and mitigating measures discussed herein.

 

Annex III

Norwegian Transparency Act

1. Reporting Subsidiaries

All of the entities listed below are fully owned indirect subsidiaries of Thermo Fisher Scientific Inc. registered in Norway, and are considered Reporting Subsidiaries under the Norwegian Act:

Life Technologies AS (and its subsidiaries)

Thermo Fisher Diagnostics AS

Fisher Scientific AS

All of Thermo Fisher’s Reporting Subsidiaries in Norway engage in sales, customer support, and marketing.

Thermo Fisher’s operations in Norway are located in Oslo and Lillestrom. As of December 31, 2024, these operations collectively employed approximately 330 colleagues, primarily within the Life Science Solutions segment.

Life Technologies AS primarily focuses on the research and development, manufacturing, and distribution of Dynabeads magnetic separation products.

Thermo Fisher Diagnostics AS specializes in in vitro diagnostics, including test kits, reagents, culture media, instruments, and associated products, to serve customers in healthcare, clinical, microbiological, pharmaceutical, and industrial laboratories.

Fisher Scientific AS serves biotech, pharmaceutical, academic, government, industrial, and healthcare customers by providing them with a range of products and services, including lab consumables, instruments and equipment, safety products, chemicals and life sciences reagents.

2. Addressing human rights and decent working conditions risks in Norwegian operations and its supply chain

All Reporting Subsidiaries adhere to the Company’s policies and procedures and are subject to the risk management strategy detailed in this Transparency Statement, including due diligence, risk assessment of operations and supply chain, and all preventive and mitigating measures discussed herein. In addition to the activities described above, sites in Norway implemented a new supplier onboarding process that includes acknowledgement of the Supplier Code of Conduct, serving as an additional preventive measure to avoid risk in our supply chain.

Signed on behalf of Thermo Fisher’s Norwegian Reporting Subsidiaries pursuant to the Norwegian Transparency Act

 

Life Technologies AS

Petrus Thomas Adrianos van der Zande Anne Haugland

Chairman Director

 

Geir Hetland Director

 

Thermo Fisher Diagnostics AS

Petrus Thomas Adrianos van der Zande Anne Omholt

Chairman Director

 

Sara Maria Carrella Director

 

Fisher Scientific AS

 

Petrus Thomas Adrianos van der Zande Anne Omholt

Chairman Director

 

Carolin Sonja Freidel Director

 

Annex IV

Swiss Ordinance on Due Diligence and Transparency in relation to Minerals and Metals from Conflict-Affected Areas and Child Labor

Reporting Subsidiaries

None of the Company’s Swiss subsidiaries meet the qualitative thresholds of import and processing of conflict minerals for the purposes of reporting under the VSoTr. Thermo Fisher also fully adheres to internationally recognized equivalent regulations on minerals and metals from conflict-affected and high-risk areas. On this basis, the Company and its Swiss subsidiaries are exempted from the conflict minerals related due diligence and reporting obligations of the VSoTr.

The entities listed below are fully owned indirect subsidiaries of Thermo Fisher Scientific Inc. registered in Switzerland and considered Reporting Entities under the VSoTr:

Fisher Clinical Services GmbH (and its subsidiaries)

Fisher Scientific AG

Life Technologies Europe B.V., Nieuwerkerk aan den IJssel, Zweigniederlassung Reinach

Thermo Fisher Scientific (Ecublens) S.à.r.l.(and its subsidiaries)

Thermo Fisher Scientific (Schweiz) AG (and its subsidiaries)

Thermo Fisher’s operations in Switzerland encompass a diverse range of functions such as packaging, sales, marketing, distribution, research and development, and consulting services. The Company trades in various products for laboratory, research, and diagnostics, as well as technical-scientific devices and packaging systems, and manages patents and licenses while providing services to unrelated parties. As of December 31, 2024, we employed approximately 1,000 colleagues supporting these operations.

Our manufacturing sites include two facilities in Allschwil and Lengnau, operating within the Laboratory Products and Services segment, and one facility in Ecublens, operating within the Analytical Instruments segment. The Lengnau site is a multipurpose biomanufacturing facility that leverages highly flexible bioproduction technologies. Our Swiss operations also include an office in Basel and a branch of the Dutch subsidiary Life Technologies Europe B.V., located in Reinach, providing sales support.

2. Addressing child labor risks in Swiss operations and its supply chain

All Reporting Subsidiaries adhere to the Company’s policies and procedures and are subject to the risk management strategy detailed in this Transparency Statement, including due diligence, risk assessment of operations and supply chain, and all preventive and mitigating measures discussed herein. In addition to the activities described above, sites in Switzerland implemented a new supplier onboarding process that includes acknowledgement of the Supplier Code of Conduct, serving as an additional preventive measure to avoid risk in our supply chain.

Annex V

UK Modern Slavery Act

1. Reporting Subsidiaries

All of the entities listed below are fully owned indirect subsidiaries of Thermo Fisher Scientific Inc. registered in the UK, and are considered Reporting Subsidiaries under the UK Act:

FEI UK Limited

Fisher Clinical Services UK Limited

Fisher Scientific UK Limited

Life Technologies BPD UK Limited

Life Technologies Limited

Oxoid Limited

Patheon UK Limited

Thermo Electron (Management Services) Limited

Thermo Electron Manufacturing Limited

Thermo Electron Limited

G&M Procter Limited

Thermo Fisher Diagnostics Limited

PPD Global Ltd

Synexus Clinical Research Limited

Evidera Ltd

Thermo Fisher’s UK operations employed approximately 6,000 colleagues as of December 31, 2024, across manufacturing facilities, research laboratories, and distribution centers.

The Company’s primary activities in the UK include research and development; manufacturing; distribution of scientific instruments and laboratory equipment; production of reagents and consumables for life sciences, healthcare, and diagnostics applications; customer support and technical services; sales and marketing activities; as well as specialized diagnostic services and biopharmaceutical contract manufacturing services, including the production of clinical and commercial-scale biologics.

2. Addressing modern slavery risks in UK operations and its supply chain

All Reporting Subsidiaries adhere to the Company’s policies and procedures and are subject to the risk management strategy detailed in this Transparency Statement, including due diligence, risk assessment of operations and supply chain, and all preventive and mitigating measures discussed herein.

  More

Notes

1 Although the present report makes contextual references to Thermo Fisher Scientific’s Responsible Minerals Sourcing Statement and due diligence activities associated with responsible mineral sourcing, the Company and its Swiss subsidiaries are exempted from the conflict minerals related due diligence and reporting obligations of the VSoTr. Additional information can be found in Annex IV.